查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1856658

猪疫苗市场（按疫苗类型、适应症、最终用户、给药途径、技术和剂型划分）－全球预测，2025-2032年

Porcine Vaccines Market by Vaccine Type, Disease Indication, End User, Route Of Administration, Technology, Dosage Form - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，猪隻疫苗市场规模将成长 31.2 亿美元，复合年增长率为 6.98%。

关键市场统计数据
基准年 2024 18.2亿美元
预计年份：2025年 19.4亿美元
预测年份 2032 31.2亿美元
复合年增长率 (%) 6.98%

清晰权威地介绍了近期科学、监管和商业趋势如何重新定义猪疫苗研发的优先事项。

由于科学创新、生产模式演变和农场需求变化等因素的交汇，猪疫苗领域正处于曲折点。核酸技术的进步、佐剂配方的改进以及更先进的给药途径正在改变人们对产品性能的预期和研发路径。同时，监管机构正在更新关于新型平台和生产品质框架的指导意见，要求研发人员和生产商更灵活地调整其临床开发计画和生产控制措施。

平台创新、监测情报和以现场为中心的交付方式的融合如何推动猪疫苗策略的系统性变革

随着平台技术和疾病标靶策略的日趋成熟，猪免疫学领域正从渐进式产品改进转向结构性变革。基于RNA的製剂、重组表现系统和病毒载体正与改良的佐剂和製剂技术结合，从而加速抗原发现和适应性生产。这种技术融合正在缩短病原体鑑定到候选药物开发之间的时间间隔，进而改变企业规划产品线和分配研发资源的方式。

对2025年美国关税政策变化所引发的连锁营运和采购影响进行全面分析

美国2025年宣布的关税政策调整对猪隻疫苗相关人员的采购、供应链经济和战略采购产生了多方面的影响。某些生技药品和生产耗材关税的提高增加了依赖国际原材料供应的供应商的投入成本，进而影响了製造商和合约服务提供者的定价策略和供应商选择。这促使许多公司重新评估其供应商布局，并加快国内或区域替代供应商的资格认证，以降低关税波动带来的风险。

将疫苗平台、目标疾病、终端用户需求、给药途径、生产技术和剂型与策略重点连结起来的综合細項分析

这种细緻的细分框架揭示了疫苗类型、适应症、最终用户、给药途径、技术和剂型在产品开发、部署策略和最终用户接受度方面的差异。疫苗类型，包括灭活疫苗、减毒疫苗、mRNA构建体、次单位疫苗和病毒载体製剂，其开发週期和监管考量各不相同。例如，灭活疫苗有裂解病毒、亚细胞和全病毒製剂，而减毒疫苗则根据异源和同源设计方案进行区分。 mRNA製剂需要根据其是否为非复製型或自扩增型进行不同的优化，而次单位疫苗则需要在次单元单位策略和蛋白质次单元策略之间进行选择。病毒载体平台可采用腺病毒或痘病毒载体骨架，每种载体在免疫学和生产方面各有优劣。

亚太、欧洲和中东地区的区域策略挑战将决定猪疫苗的监管、分发和推广路径。

区域动态对研究重点、监管策略和商业化途径的形成至关重要。在美洲，大型商业营运和完善的兽医服务网络推动了对先进平台解决方案和精准疫苗接种策略的需求，而监管重点则放在生产品质和上市后监测上，从而形成了一个异质性生态系统。相较之下，欧洲、中东和非洲的法律规范和基础设施差异显着，因此需要能够适应高度监管市场以及低温运输和兽医服务能力有限的地区的灵活商业化模式。亚太地区某些中心城市创新应用迅速，而其他地区则拥有庞大的小农户群体，因此需要采取双轨制策略，在部署高科技平台的同时，兼顾成本效益高、便于田间使用的疫苗方案。

创新主导开发商、契约製造和策略伙伴如何塑造猪疫苗价值链中的竞争差异化

竞争格局呈现出由成熟的动物用药品公司、专业生物技术创新企业、受託製造厂商)和学术研究中心组成的多元化格局。规模较大的研发企业优先考虑平台多元化，以平衡近期商业化产品和长期在临床实验药物，并经常寻求将临床开发实力与可扩展生产技术相结合的伙伴关係。契约製造和 CDMO 的角色日益重要，它们使较小的创新企业能够获得符合 GMP 标准的生产，并使大型企业能够在不过度投资固定资产的情况下灵活管理产能。

为开发人员和相关人员提供切实有效的策略建议，以加快猪疫苗领域的平台准备、供应链弹性以及终端用户采纳率。

产业领导者应采取三管齐下的策略方针，将科学研究能力与营运韧性和市场进入便利化结合。例如，在维持优化传统产品线的同时，扩大RNA和重组DNA技术能力，既能快速应对新出现的威胁，也能确保在疫情期间产品的稳定供应。其次，为降低贸易中断和关税导致的成本波动风险，应透过寻找替代原材料来源、投资区域生产或填充加工能力以及加强低温运输基础设施来建立供应链韧性。

一种严谨的多资讯来源调查方法，结合了专家访谈、监管机构研究、科学文献综述和基于情境的供应链分析。

该研究结合了定性和定量数据，包括科学文献、监管指导文件、行业披露资讯、技术简报以及对价值链各环节专家的访谈。证据综合分析优先考虑了平台免疫学和製剂科学的同行评审研究、与生物製药和新产品相关的监管指南，以及来自生产和分销相关人员的营运文件，从而全面观点技术、供应和应用趋势。

综合各项结论，强调技术融合、供应链韧性和协作方法是未来猪隻免疫学发展的基础。

猪疫苗生态系统日益受到创新、务实和不断变化的政策环境三者相互作用的影响。平台技术的进步为提高疫苗的保护范围和反应速度提供了切实的机会，但要实现这些益处，需要同步投资于生产灵活性、监管策略和现场供给能力。同时，贸易政策的变化和供应链压力凸显了地域多元化和供应商合格对于保障供应连续性和控製成本风险的重要性。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 先进的mRNA疫苗平台因其能够快速控制猪传染病而越来越受欢迎。
  • 将新型奈米颗粒佐剂整合到猪流感疫苗中以提高其效力
  • 政府资助计画旨在加速非洲猪瘟疫苗的商业化进程
  • 一家生物技术企业与一家大型动物用药品公司建立策略伙伴关係，共同开发下一代猪用疫苗
  • 引入数位化诊断工具，用于在接种疫苗前即时监测猪群的免疫状态。
  • 随着生猪养殖规模的扩大，对能够预防多种猪呼吸道病原体的广谱多效价疫苗的需求日益增长。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依疫苗类型分類的猪隻疫苗市场

  • 惰性
    • 分裂病毒
    • 亚细胞
    • 整个病毒
  • 活病毒疫苗
    • 异质
    • 同源
  • MRNA
    • 未扩增的mRNA
    • 自扩增mRNA
  • 次单元
    • 多醣体次单元
    • 蛋白质次单元
  • 病毒载体
    • 腺病毒载体
    • 痘病毒载体

9. 依适应症分類的猪隻疫苗市场

  • 传统猪瘟
  • 丹毒
  • 猪繁殖与呼吸综合症
  • 猪流感

第十章 以最终用户分類的猪隻疫苗市场

  • 商业农场
  • 研究所
  • 小农场
  • 兽医诊所

第十一章 依给药途径分類的猪隻疫苗市场

  • 皮内注射
  • 肌肉内注射
  • 鼻腔
  • 口服
  • 皮下

12. 按技术分類的猪隻疫苗市场

  • 传统的
    • 减毒活病毒疫苗
    • 基尔德霍尔
  • DNA
  • 重组
    • 细菌表达
    • 昆虫细胞表达
    • 酵母表达
  • RNA
  • VLP

第十三章 猪疫苗市场按剂型划分

  • 乳液
  • 液体
  • 冷冻干燥

第十四章 各地区猪隻疫苗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 猪疫苗市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国猪疫苗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Zoetis Inc.
    • Boehringer Ingelheim International GmbH
    • Merck & Co., Inc.
    • Ceva Sante Animale SA
    • Elanco Animal Health Incorporated
    • HIPRA, SA
    • Vetoquinol SA
    • Phibro Animal Health Corporation
    • Virbac SA
    • Bioveta, as
Product Code: MRR-742BD5183CF6

The Porcine Vaccines Market is projected to grow by USD 3.12 billion at a CAGR of 6.98% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.82 billion
Estimated Year [2025] USD 1.94 billion
Forecast Year [2032] USD 3.12 billion
CAGR (%) 6.98%

A clear, authoritative primer explaining how recent scientific, regulatory, and operational changes are redefining priorities in porcine vaccine development

The porcine vaccine arena stands at an inflection point driven by converging scientific innovation, evolving production modalities, and shifting farm-level needs. Advances in nucleic acid technologies, improved adjuvant formulations, and more refined delivery routes have altered both product performance expectations and development pathways. Meanwhile, regulatory authorities are updating guidance on novel platforms and manufacturing quality frameworks, which requires developers and producers to adapt clinical development plans and manufacturing controls with greater agility.

Operational pressures across supply chains and the increasing focus on biosafety and traceability are reshaping procurement practices among commercial farms, veterinary hospitals, and research institutes. As stakeholders prioritize resilience and predictability, there is a growing premium on vaccines that combine robust efficacy profiles with simplified administration and storage requirements. Collectively, these dynamics are redefining investment priorities, strategic partnerships, and pipeline development across the sector.

How converging platform innovations, surveillance intelligence, and field-centric delivery approaches are driving systemic transformation in porcine vaccine strategies

The landscape for porcine immunization is moving from incremental product improvement toward structural transformation as platform technologies and disease targeting strategies mature. RNA-based modalities, recombinant expression systems, and viral vectors are converging with improved adjuvant and formulation science to enable faster antigen discovery and adaptable manufacturing. This technological convergence shortens the interval between pathogen identification and candidate deployment, thereby changing how companies plan pipelines and allocate R&D resources.

Concurrently, disease surveillance networks and data integration across farms and veterinary services are enabling earlier outbreak detection and more precise vaccine deployment strategies. These capabilities are encouraging stakeholders to invest in modular production capacity, cold chain innovations, and alternative routes of administration that reduce labor and stress at the herd level. As a result, strategic emphasis is shifting toward platform flexibility, cross-protection potential, and ease of field use, which together are driving new collaboration models between developers, contract manufacturers, and end users.

Comprehensive analysis of the cascading operational and sourcing consequences that resulted from the United States tariff changes implemented in 2025

US tariff policy changes announced in 2025 have had multifaceted implications across sourcing, supply chain economics, and strategic procurement for porcine vaccine stakeholders. Increased duties on selected biologics inputs and certain manufacturing consumables elevated input costs for suppliers that rely on international raw material flows, which in turn influenced pricing strategies and vendor selection for manufacturers and contract service providers. In response, many organizations reassessed supplier footprints and accelerated qualification of alternative domestic or regional suppliers to reduce exposure to tariff variability.

These adjustments also pushed manufacturers to evaluate inventory policies and to strengthen contractual terms with upstream suppliers to secure supply continuity. For end users such as commercial farms and veterinary networks, procurement practices evolved toward longer-term purchasing agreements and collaborative planning to smooth supply disruptions. Policymakers and industry groups engaged in dialogue to clarify tariff scope and to explore mitigations, including targeted exemptions, streamlined customs processes, and incentives for local production capacity to reinforce resilience and hedging against future trade volatility.

An integrated segmentation analysis linking vaccine platforms, disease targets, end-user needs, administration routes, production technologies, and dosage formats to strategic priorities

A nuanced segmentation framework reveals how product development, deployment strategies, and end-user uptake diverge across vaccine type, disease indication, end user, route of administration, technology, and dosage form. Vaccine type distinctions between Inactivated formats, Live Attenuated preparations, mRNA constructs, Subunit vaccines, and Virus Vectored solutions shape development timelines and regulatory considerations; for example, Inactivated vaccines vary further as Split Virus, Subcellular, and Whole Virus formulations, while Live Attenuated approaches are differentiated by Heterologous and Homologous design choices. mRNA modalities require different optimization depending on whether they are Non-Amplifying or Self-Amplifying constructs, and Subunit vaccines call for choices between Polysaccharide Subunit and Protein Subunit strategies. Virus Vectored platforms may leverage Adenovirus Vector or Poxvirus Vector backbones, each with distinct immunologic and manufacturing trade-offs.

Disease indication segmentation including Classical Swine Fever, Erysipelas, Porcine Reproductive And Respiratory Syndrome, and Swine Influenza directs antigen selection priorities and field trial design. End users such as Commercial Farms, Research Institutes, Smallholder Farms, and Veterinary Hospitals present contrasting adoption criteria that influence dosing regimens, packaging, and service models. Route of administration choices spanning Intradermal, Intramuscular, Intranasal, Oral, and Subcutaneous determine product format and on-farm labor implications. Underlying technology categories of Conventional, DNA, Recombinant, RNA, and VLP further shape development pathways, with Conventional pathways subdividing into Attenuated Live and Killed Whole approaches and Recombinant strategies differentiating between Bacteria Expressed, Insect Cell Expressed, and Yeast Expressed production methods. Dosage form variants across Emulsion, Liquid, and Lyophilized formats affect logistics and shelf-life considerations. Taken together, this segmentation matrix clarifies where technical investment and commercialization focus will yield the greatest operational and clinical impact.

Regional strategic imperatives across the Americas, Europe, Middle East & Africa, and Asia-Pacific that determine regulatory, distribution, and adoption pathways for porcine vaccines

Regional dynamics are critical for shaping research priorities, regulatory strategy, and commercialization approaches. The Americas present a heterogeneous ecosystem in which large commercial operations and sophisticated veterinary service networks drive demand for advanced platform solutions and precision immunization strategies, while regulatory scrutiny emphasizes manufacturing quality and post-licensure surveillance. In contrast, Europe, Middle East & Africa exhibits wide variability across regulatory frameworks and infrastructure, requiring adaptable commercialization models that can accommodate both highly regulated markets and areas with more constrained cold chain or veterinary services capacity. Asia-Pacific combines rapid innovation adoption in certain hubs with extensive smallholder populations in other geographies, necessitating a dual-track approach that balances high-tech platform deployment alongside cost-effective, field-friendly vaccine options.

These regional contrasts influence R&D prioritization, partnership models, and distribution strategies. For developers and suppliers, success depends on tailoring dossiers and evidence packages to regulatory expectations in each region while designing logistics and service models that match local end-user capabilities. Consequently, strategic regional investments in manufacturing, cold chain enhancements, and localized training programs can materially affect uptake and long-term adoption trajectories across geographies.

How innovation-led developers, contract manufacturers, and strategic collaborations are shaping competitive differentiation across the porcine vaccine value chain

The competitive landscape is characterized by a mix of established animal health corporations, specialized biotech innovators, contract manufacturing organizations, and academic research centers. Leading developers emphasize platform diversification to balance near-term commercial products with longer-term investigational candidates, often pursuing partnerships that combine clinical development strength with scalable manufacturing expertise. Contract manufacturers and CDMOs are playing an increasingly pivotal role, enabling smaller innovators to access GMP-compliant production and allowing larger firms to manage capacity flexibility without over-investing in fixed assets.

Strategic behaviors among companies include vertical integration of supply chains, targeted acquisitions to close capability gaps in novel platforms, and collaborative research agreements that accelerate antigen discovery and immunogenicity testing. Firms that invest in robust regulatory affairs teams and post-approval surveillance capabilities achieve smoother product rollouts and stronger stakeholder trust. Meanwhile, companies prioritizing field-centric design-such as simplified dosing regimens, thermostable formulations, and minimally invasive delivery-are better positioned to capture adoption among diverse end users. Overall, sustained competitive advantage arises from the intersection of scientific excellence, manufacturing resilience, and deep understanding of end-user operational needs.

High-impact, practical strategic recommendations for developers and stakeholders to accelerate platform readiness, supply resilience, and end-user adoption in the porcine vaccine sector

Industry leaders should adopt a three-pronged strategic approach that aligns scientific capability with operational resilience and market access facilitation. First, prioritize platform investments that deliver both agility and breadth; for example, expanding RNA and recombinant capabilities while maintaining optimized conventional pipelines can enable both rapid response to emergent threats and stable product offerings for endemic diseases. Second, build supply chain resilience by qualifying alternative raw material sources, investing in regional production or fill-finish capacity, and enhancing cold chain infrastructure to reduce vulnerability to trade disruptions and tariff-induced cost shifts.

Third, strengthen end-user engagement by co-developing administration and training programs with veterinary networks and farm groups so that product attributes are matched to field realities. In parallel, pursue regulatory engagement early in development to align on evidence requirements for novel platforms and to expedite approval pathways. Finally, consider flexible commercial models such as subscription-style supply agreements or tiered pricing to expand reach across different end-user segments while maintaining sustainable revenue streams. These combined actions will help organizations convert scientific advances into reliable, accessible immunization solutions.

A rigorous, multi-source research methodology integrating primary expert interviews, regulatory review, scientific literature synthesis, and scenario-based supply chain analysis

This research synthesized qualitative and quantitative inputs across scientific literature, regulatory guidance documents, industry disclosures, technical briefings, and interviews with subject-matter experts across the value chain. Evidence synthesis prioritized peer-reviewed studies on platform immunology and formulation science, regulatory guidelines relevant to biologicals and novel modalities, and operational documentation from manufacturing and distribution stakeholders to create a comprehensive perspective on technology, supply, and adoption trends.

In addition to secondary research, primary engagements included structured interviews with laboratory researchers, manufacturing leaders, regulatory affairs professionals, and farm-level practitioners to validate assumptions and surface practical adoption barriers. Triangulation techniques were used to reconcile differing viewpoints and to ensure that conclusions reflect both scientific plausibility and operational feasibility. Analytic methods emphasized thematic coding for qualitative inputs and scenario analysis for supply chain and policy impact assessment, thereby providing robust, actionable insights for decision-makers.

Concluding synthesis emphasizing technology convergence, supply resilience, and collaborative approaches as the foundations for future progress in porcine immunization

The porcine vaccine ecosystem is increasingly defined by the interplay of technological innovation, operational pragmatism, and evolving policy environments. Advances in platform technologies offer genuine opportunities to improve protection breadth and speed of response, but realizing those gains requires synchronized investment in manufacturing flexibility, regulatory strategy, and field delivery capabilities. In parallel, trade policy shifts and supply chain pressure underscore the importance of regional diversification and supplier qualification to protect continuity of supply and to manage cost exposure.

Going forward, stakeholders that combine platform agility with deep end-user engagement and resilient supply arrangements will be best positioned to convert scientific progress into measurable animal health outcomes. Cross-sector collaboration-spanning developers, service providers, regulators, and farm networks-will remain essential to accelerate responsible adoption and to ensure that innovations translate into sustainable improvements in disease control and farm productivity.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advanced mRNA vaccine platforms gaining traction for rapid porcine disease control
  • 5.2. Integration of novel nanoparticle adjuvants to enhance porcine influenza vaccine efficacy
  • 5.3. Government funding initiatives accelerating African swine fever vaccine commercialization efforts
  • 5.4. Strategic partnerships between biotech startups and major animal health companies to co-develop next-generation porcine vaccines
  • 5.5. Adoption of digital diagnostic tools for real-time monitoring of porcine herd immune status before vaccination
  • 5.6. Rising demand for broad-spectrum multivalent vaccines targeting multiple swine respiratory pathogens in growing herds

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Porcine Vaccines Market, by Vaccine Type

  • 8.1. Inactivated
    • 8.1.1. Split Virus
    • 8.1.2. Subcellular
    • 8.1.3. Whole Virus
  • 8.2. Live Attenuated
    • 8.2.1. Heterologous
    • 8.2.2. Homologous
  • 8.3. MRNA
    • 8.3.1. Non Amplifying MRNA
    • 8.3.2. Self Amplifying MRNA
  • 8.4. Subunit
    • 8.4.1. Polysaccharide Subunit
    • 8.4.2. Protein Subunit
  • 8.5. Virus Vectored
    • 8.5.1. Adenovirus Vector
    • 8.5.2. Poxvirus Vector

9. Porcine Vaccines Market, by Disease Indication

  • 9.1. Classical Swine Fever
  • 9.2. Erysipelas
  • 9.3. Porcine Reproductive And Respiratory Syndrome
  • 9.4. Swine Influenza

10. Porcine Vaccines Market, by End User

  • 10.1. Commercial Farm
  • 10.2. Research Institute
  • 10.3. Smallholder Farm
  • 10.4. Veterinary Hospital

11. Porcine Vaccines Market, by Route Of Administration

  • 11.1. Intradermal
  • 11.2. Intramuscular
  • 11.3. Intranasal
  • 11.4. Oral
  • 11.5. Subcutaneous

12. Porcine Vaccines Market, by Technology

  • 12.1. Conventional
    • 12.1.1. Attenuated Live
    • 12.1.2. Killed Whole
  • 12.2. DNA
  • 12.3. Recombinant
    • 12.3.1. Bacteria Expressed
    • 12.3.2. Insect Cell Expressed
    • 12.3.3. Yeast Expressed
  • 12.4. RNA
  • 12.5. VLP

13. Porcine Vaccines Market, by Dosage Form

  • 13.1. Emulsion
  • 13.2. Liquid
  • 13.3. Lyophilized

14. Porcine Vaccines Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Porcine Vaccines Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Porcine Vaccines Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Zoetis Inc.
    • 17.3.2. Boehringer Ingelheim International GmbH
    • 17.3.3. Merck & Co., Inc.
    • 17.3.4. Ceva Sante Animale S.A.
    • 17.3.5. Elanco Animal Health Incorporated
    • 17.3.6. HIPRA, S.A.
    • 17.3.7. Vetoquinol S.A.
    • 17.3.8. Phibro Animal Health Corporation
    • 17.3.9. Virbac S.A.
    • 17.3.10. Bioveta, a.s.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PORCINE VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PORCINE VACCINES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PORCINE VACCINES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PORCINE VACCINES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS PORCINE VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL PORCINE VACCINES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. PORCINE VACCINES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. PORCINE VACCINES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PORCINE VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PORCINE VACCINES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PORCINE VACCINES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PORCINE VACCINES MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PORCINE VACCINES MARKET SIZE, BY INACTIVATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PORCINE VACCINES MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PORCINE VACCINES MARKET SIZE, BY INACTIVATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PORCINE VACCINES MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PORCINE VACCINES MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PORCINE VACCINES MARKET SIZE, BY SPLIT VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PORCINE VACCINES MARKET SIZE, BY SPLIT VIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PORCINE VACCINES MARKET SIZE, BY SPLIT VIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PORCINE VACCINES MARKET SIZE, BY SPLIT VIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PORCINE VACCINES MARKET SIZE, BY SPLIT VIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PORCINE VACCINES MARKET SIZE, BY SPLIT VIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBCELLULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBCELLULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBCELLULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBCELLULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBCELLULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBCELLULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PORCINE VACCINES MARKET SIZE, BY WHOLE VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PORCINE VACCINES MARKET SIZE, BY WHOLE VIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PORCINE VACCINES MARKET SIZE, BY WHOLE VIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PORCINE VACCINES MARKET SIZE, BY WHOLE VIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PORCINE VACCINES MARKET SIZE, BY WHOLE VIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PORCINE VACCINES MARKET SIZE, BY WHOLE VIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PORCINE VACCINES MARKET SIZE, BY HETEROLOGOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PORCINE VACCINES MARKET SIZE, BY HETEROLOGOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PORCINE VACCINES MARKET SIZE, BY HETEROLOGOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PORCINE VACCINES MARKET SIZE, BY HETEROLOGOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PORCINE VACCINES MARKET SIZE, BY HETEROLOGOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PORCINE VACCINES MARKET SIZE, BY HETEROLOGOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PORCINE VACCINES MARKET SIZE, BY HOMOLOGOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PORCINE VACCINES MARKET SIZE, BY HOMOLOGOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PORCINE VACCINES MARKET SIZE, BY HOMOLOGOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PORCINE VACCINES MARKET SIZE, BY HOMOLOGOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PORCINE VACCINES MARKET SIZE, BY HOMOLOGOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PORCINE VACCINES MARKET SIZE, BY HOMOLOGOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PORCINE VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PORCINE VACCINES MARKET SIZE, BY MRNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PORCINE VACCINES MARKET SIZE, BY MRNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PORCINE VACCINES MARKET SIZE, BY MRNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PORCINE VACCINES MARKET SIZE, BY MRNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PORCINE VACCINES MARKET SIZE, BY MRNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PORCINE VACCINES MARKET SIZE, BY MRNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PORCINE VACCINES MARKET SIZE, BY NON AMPLIFYING MRNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PORCINE VACCINES MARKET SIZE, BY NON AMPLIFYING MRNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PORCINE VACCINES MARKET SIZE, BY NON AMPLIFYING MRNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PORCINE VACCINES MARKET SIZE, BY NON AMPLIFYING MRNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PORCINE VACCINES MARKET SIZE, BY NON AMPLIFYING MRNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PORCINE VACCINES MARKET SIZE, BY NON AMPLIFYING MRNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PORCINE VACCINES MARKET SIZE, BY SELF AMPLIFYING MRNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PORCINE VACCINES MARKET SIZE, BY SELF AMPLIFYING MRNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PORCINE VACCINES MARKET SIZE, BY SELF AMPLIFYING MRNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PORCINE VACCINES MARKET SIZE, BY SELF AMPLIFYING MRNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PORCINE VACCINES MARKET SIZE, BY SELF AMPLIFYING MRNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PORCINE VACCINES MARKET SIZE, BY SELF AMPLIFYING MRNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBUNIT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBUNIT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBUNIT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBUNIT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBUNIT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBUNIT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PORCINE VACCINES MARKET SIZE, BY POLYSACCHARIDE SUBUNIT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PORCINE VACCINES MARKET SIZE, BY POLYSACCHARIDE SUBUNIT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PORCINE VACCINES MARKET SIZE, BY POLYSACCHARIDE SUBUNIT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PORCINE VACCINES MARKET SIZE, BY POLYSACCHARIDE SUBUNIT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PORCINE VACCINES MARKET SIZE, BY POLYSACCHARIDE SUBUNIT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PORCINE VACCINES MARKET SIZE, BY POLYSACCHARIDE SUBUNIT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PORCINE VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PORCINE VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PORCINE VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PORCINE VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PORCINE VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PORCINE VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PORCINE VACCINES MARKET SIZE, BY ADENOVIRUS VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PORCINE VACCINES MARKET SIZE, BY ADENOVIRUS VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PORCINE VACCINES MARKET SIZE, BY ADENOVIRUS VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PORCINE VACCINES MARKET SIZE, BY ADENOVIRUS VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PORCINE VACCINES MARKET SIZE, BY ADENOVIRUS VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PORCINE VACCINES MARKET SIZE, BY ADENOVIRUS VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PORCINE VACCINES MARKET SIZE, BY POXVIRUS VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PORCINE VACCINES MARKET SIZE, BY POXVIRUS VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PORCINE VACCINES MARKET SIZE, BY POXVIRUS VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PORCINE VACCINES MARKET SIZE, BY POXVIRUS VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PORCINE VACCINES MARKET SIZE, BY POXVIRUS VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PORCINE VACCINES MARKET SIZE, BY POXVIRUS VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PORCINE VACCINES MARKET SIZE, BY CLASSICAL SWINE FEVER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PORCINE VACCINES MARKET SIZE, BY CLASSICAL SWINE FEVER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PORCINE VACCINES MARKET SIZE, BY CLASSICAL SWINE FEVER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PORCINE VACCINES MARKET SIZE, BY CLASSICAL SWINE FEVER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PORCINE VACCINES MARKET SIZE, BY CLASSICAL SWINE FEVER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PORCINE VACCINES MARKET SIZE, BY CLASSICAL SWINE FEVER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PORCINE VACCINES MARKET SIZE, BY ERYSIPELAS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PORCINE VACCINES MARKET SIZE, BY ERYSIPELAS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PORCINE VACCINES MARKET SIZE, BY ERYSIPELAS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PORCINE VACCINES MARKET SIZE, BY ERYSIPELAS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PORCINE VACCINES MARKET SIZE, BY ERYSIPELAS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PORCINE VACCINES MARKET SIZE, BY ERYSIPELAS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PORCINE VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PORCINE VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PORCINE VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PORCINE VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PORCINE VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PORCINE VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PORCINE VACCINES MARKET SIZE, BY SWINE INFLUENZA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PORCINE VACCINES MARKET SIZE, BY SWINE INFLUENZA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL PORCINE VACCINES MARKET SIZE, BY SWINE INFLUENZA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL PORCINE VACCINES MARKET SIZE, BY SWINE INFLUENZA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL PORCINE VACCINES MARKET SIZE, BY SWINE INFLUENZA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL PORCINE VACCINES MARKET SIZE, BY SWINE INFLUENZA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL PORCINE VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL PORCINE VACCINES MARKET SIZE, BY COMMERCIAL FARM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL PORCINE VACCINES MARKET SIZE, BY COMMERCIAL FARM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL PORCINE VACCINES MARKET SIZE, BY COMMERCIAL FARM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL PORCINE VACCINES MARKET SIZE, BY COMMERCIAL FARM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL PORCINE VACCINES MARKET SIZE, BY COMMERCIAL FARM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL PORCINE VACCINES MARKET SIZE, BY COMMERCIAL FARM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL PORCINE VACCINES MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL PORCINE VACCINES MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL PORCINE VACCINES MARKET SIZE, BY RESEARCH INSTITUTE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL PORCINE VACCINES MARKET SIZE, BY RESEARCH INSTITUTE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL PORCINE VACCINES MARKET SIZE, BY RESEARCH INSTITUTE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL PORCINE VACCINES MARKET SIZE, BY RESEARCH INSTITUTE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL PORCINE VACCINES MARKET SIZE, BY SMALLHOLDER FARM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL PORCINE VACCINES MARKET SIZE, BY SMALLHOLDER FARM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL PORCINE VACCINES MARKET SIZE, BY SMALLHOLDER FARM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL PORCINE VACCINES MARKET SIZE, BY SMALLHOLDER FARM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL PORCINE VACCINES MARKET SIZE, BY SMALLHOLDER FARM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL PORCINE VACCINES MARKET SIZE, BY SMALLHOLDER FARM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL PORCINE VACCINES MARKET SIZE, BY VETERINARY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL PORCINE VACCINES MARKET SIZE, BY VETERINARY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL PORCINE VACCINES MARKET SIZE, BY VETERINARY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL PORCINE VACCINES MARKET SIZE, BY VETERINARY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL PORCINE VACCINES MARKET SIZE, BY VETERINARY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL PORCINE VACCINES MARKET SIZE, BY VETERINARY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRADERMAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRADERMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRADERMAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRADERMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRADERMAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRANASAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRANASAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRANASAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRANASAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRANASAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL PORCINE VACCINES MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL PORCINE VACCINES MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL PORCINE VACCINES MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL PORCINE VACCINES MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL PORCINE VACCINES MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL PORCINE VACCINES MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL PORCINE VACCINES MARKET SIZE, BY ATTENUATED LIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL PORCINE VACCINES MARKET SIZE, BY ATTENUATED LIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL PORCINE VACCINES MARKET SIZE, BY ATTENUATED LIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL PORCINE VACCINES MARKET SIZE, BY ATTENUATED LIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL PORCINE VACCINES MARKET SIZE, BY ATTENUATED LIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL PORCINE VACCINES MARKET SIZE, BY ATTENUATED LIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL PORCINE VACCINES MARKET SIZE, BY KILLED WHOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL PORCINE VACCINES MARKET SIZE, BY KILLED WHOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL PORCINE VACCINES MARKET SIZE, BY KILLED WHOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL PORCINE VACCINES MARKET SIZE, BY KILLED WHOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL PORCINE VACCINES MARKET SIZE, BY KILLED WHOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL PORCINE VACCINES MARKET SIZE, BY KILLED WHOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL PORCINE VACCINES MARKET SIZE, BY DNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL PORCINE VACCINES MARKET SIZE, BY DNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL PORCINE VACCINES MARKET SIZE, BY DNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL PORCINE VACCINES MARKET SIZE, BY DNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL PORCINE VACCINES MARKET SIZE, BY DNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL PORCINE VACCINES MARKET SIZE, BY DNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL PORCINE VACCINES MARKET SIZE, BY BACTERIA EXPRESSED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL PORCINE VACCINES MARKET SIZE, BY BACTERIA EXPRESSED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL PORCINE VACCINES MARKET SIZE, BY BACTERIA EXPRESSED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL PORCINE VACCINES MARKET SIZE, BY BACTERIA EXPRESSED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL PORCINE VACCINES MARKET SIZE, BY BACTERIA EXPRESSED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL PORCINE VACCINES MARKET SIZE, BY BACTERIA EXPRESSED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL PORCINE VACCINES MARKET SIZE, BY INSECT CELL EXPRESSED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL PORCINE VACCINES MARKET SIZE, BY INSECT CELL EXPRESSED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL PORCINE VACCINES MARKET SIZE, BY INSECT CELL EXPRESSED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL PORCINE VACCINES MARKET SIZE, BY INSECT CELL EXPRESSED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL PORCINE VACCINES MARKET SIZE, BY INSECT CELL EXPRESSED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL PORCINE VACCINES MARKET SIZE, BY INSECT CELL EXPRESSED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL PORCINE VACCINES MARKET SIZE, BY YEAST EXPRESSED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL PORCINE VACCINES MARKET SIZE, BY YEAST EXPRESSED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL PORCINE VACCINES MARKET SIZE, BY YEAST EXPRESSED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL PORCINE VACCINES MARKET SIZE, BY YEAST EXPRESSED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL PORCINE VACCINES MARKET SIZE, BY YEAST EXPRESSED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL PORCINE VACCINES MARKET SIZE, BY YEAST EXPRESSED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL PORCINE VACCINES MARKET SIZE, BY RNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL PORCINE VACCINES MARKET SIZE, BY RNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL PORCINE VACCINES MARKET SIZE, BY RNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL PORCINE VACCINES MARKET SIZE, BY RNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL PORCINE VACCINES MARKET SIZE, BY RNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL PORCINE VACCINES MARKET SIZE, BY RNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL PORCINE VACCINES MARKET SIZE, BY VLP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL PORCINE VACCINES MARKET SIZE, BY VLP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL PORCINE VACCINES MARKET SIZE, BY VLP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL PORCINE VACCINES MARKET SIZE, BY VLP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL PORCINE VACCINES MARKET SIZE, BY VLP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL PORCINE VACCINES MARKET SIZE, BY VLP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL PORCINE VACCINES MARKET SIZE, BY EMULSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL PORCINE VACCINES MARKET SIZE, BY EMULSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL PORCINE VACCINES MARKET SIZE, BY EMULSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL PORCINE VACCINES MARKET SIZE, BY EMULSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL PORCINE VACCINES MARKET SIZE, BY EMULSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL PORCINE VACCINES MARKET SIZE, BY EMULSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL PORCINE VACCINES MARKET SIZE, BY LIQUID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL PORCINE VACCINES MARKET SIZE, BY LIQUID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL PORCINE VACCINES MARKET SIZE, BY LIQUID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL PORCINE VACCINES MARKET SIZE, BY LIQUID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL PORCINE VACCINES MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL PORCINE VACCINES MARKET SIZE, BY LIQUID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL PORCINE VACCINES MARKET SIZE, BY LYOPHILIZED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL PORCINE VACCINES MARKET SIZE, BY LYOPHILIZED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL PORCINE VACCINES MARKET SIZE, BY LYOPHILIZED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL PORCINE VACCINES MARKET SIZE, BY LYOPHILIZED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL PORCINE VACCINES MARKET SIZE, BY LYOPHILIZED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL PORCINE VACCINES MARKET SIZE, BY LYOPHILIZED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL PORCINE VACCINES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL PORCINE VACCINES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS PORCINE VACCINES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS PORCINE VACCINES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2025-2032 (USD MILLION)
  • TABLE 291. AMERICAS PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2024 (USD MILLION)
  • TABLE 292. AMERICAS PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2025-2032 (USD MILLION)
  • TABLE 293. AMERICAS PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 294. AMERICAS PORCINE VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 295. AMERICAS PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2024 (USD MILLION)
  • TABLE 296. AMERICAS PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2025-2032 (USD MILLION)
  • TABLE 297. AMERICAS PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2024 (USD MILLION)
  • TABLE 298. AMERICAS PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2025-2032 (USD MILLION)
  • TABLE 299. AMERICAS PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 300. AMERICAS PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 301. AMERICAS PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 302. AMERICAS PORCINE VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 303. AMERICAS PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 304. AMERICAS PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 305. AMERICAS PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 306. AMERICAS PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 307. AMERICAS PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2024 (USD MILLION)
  • TABLE 308. AMERICAS PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2025-2032 (USD MILLION)
  • TABLE 309. AMERICAS PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
  • TABLE 310. AMERICAS PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2025-2032 (USD MILLION)
  • TABLE 311. AMERICAS PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 312. AMERICAS PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 313. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 314. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 315. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 316. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 317. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2024 (USD MILLION)
  • TABLE 318. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2025-2032 (USD MILLION)
  • TABLE 319. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2024 (USD MILLION)
  • TABLE 320. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2025-2032 (USD MILLION)
  • TABLE 321. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 322. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 323. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2024 (USD MILLION)
  • TABLE 324. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2025-2032 (USD MILLION)
  • TABLE 325. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2024 (USD MILLION)
  • TABLE 326. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2025-2032 (USD MILLION)
  • TABLE 327. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 328. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 329. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 330. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 331. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 332. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 333. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 334. NORTH AMERICA PORCINE VACC